Authors
Maud Lemoine, Yusuke Shimakawa, Shevanthi Nayagam, Mustapha Khalil, Penda Suso, Jo Lloyd, Robert Goldin, Harr-Freeya Njai, Gibril Ndow, Makie Taal, Graham Cooke, Umberto d'Alessandro, Muriel Vray, Papa Saliou Mbaye, Ramou Njie, Vincent Mallet, Mark Thursz
Publication date
2016/8/1
Journal
Gut
Volume
65
Issue
8
Pages
1369-1376
Publisher
BMJ Publishing Group
Description
Background
Simple and inexpensive non-invasive fibrosis tests are highly needed but have been poorly studied in sub-Saharan Africa.
Methods
Using liver histology as a gold standard, we developed a novel index using routine laboratory tests to predict significant fibrosis in patients with chronic HBV infection in The Gambia, West Africa. We prospectively assessed the diagnostic accuracy of the novel index, Fibroscan, aspartate transaminase-to-platelet ratio index (APRI), and Fib-4 in Gambian patients with CHB (training set) and also in French and Senegalese CHB cohorts (validation sets).
Results
Of 135 consecutive treatment-naïve patients with CHB who had liver biopsy, 39% had significant fibrosis (Metavir fibrosis stage ≥F2) and 15% had cirrhosis (F4). In multivariable analysis, gamma-glutamyl transpeptidase (GGT) and platelet count were independent predictors of significant fibrosis. Consequently, GGT-to …
Scholar articles
M Lemoine, Y Shimakawa, S Nayagam, M Khalil… - Gut, 2016